Long-term outcomes of conservative management in moyamoya disease patients and their relatives

Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives

This study looks at how well non-surgical treatments work for people with moyamoya disease and their family members over time.

Quick facts

• Study type: Observational
• Enrollment: 400 (estimated)
• Ages: 2 Years to 60 Years
• Sex: All
• Sponsor: Beijing Tiantan Hospital (Academic / other)
• Locations: 1 site (Beijing, Beijing Municipality)
• Trial ID: NCT05332756 on ClinicalTrials.gov

What this trial studies

This study investigates the long-term outcomes of conservative management in patients diagnosed with moyamoya disease and their first-degree relatives. Moyamoya disease is a chronic cerebrovascular condition characterized by the narrowing of the internal carotid arteries and the formation of abnormal blood vessels. The study aims to understand the effectiveness of conservative treatment options and explore the potential genetic and environmental factors contributing to the disease's pathogenesis. Participants will be monitored over time to assess their health outcomes and any manifestations in their relatives.

Who should consider this trial

Good fit: Ideal candidates include individuals aged 2-60 years with a clinical diagnosis of moyamoya disease who are receiving conservative management.

Not a fit: Patients with concomitant diseases or conditions that could interfere with the study outcomes may not benefit from participation.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the long-term management of moyamoya disease, potentially improving patient care and outcomes.

How similar studies have performed: While there have been studies on moyamoya disease, the specific focus on long-term conservative management outcomes in both patients and their relatives is relatively novel.

Eligibility criteria

Inclusion Criteria:

1. Patients with age between 2-60 years;
2. A clinical diagnosis of moyamoya disease, including unilateral and bilateral disease.
3. Patients are medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
4. Capable of understanding the purpose and risk of the study and has signed the informed consent. If the participant is not capable of this at the time of enrollment, a legally authorized representative will provide written informed consent in accordance with all regulations.
5. Ability to comply with study follow-up.

Exclusion Criteria:

1. Concomitant other diseases, including systemic vasculitis, neurofibroma, meningitis, sickle cell disease, down's syndrome, and previous basilar radiotherapy.
2. Patients with cardiogenic embolism, including a history of atrial fibrillation, valvular disease or cardiac valve replacement.
3. Patients are allergic to the contrast agents.
4. Patients are treated with direct, indirect, or combined revascularization depending on the presentation.
5. Physical or subjective failure to cooperate with the examination or serious comorbid diseases.
6. Patients are unable or unlikely to return for follow-up visits.
7. Any other reasons that, in the opinion of the investigators, make the participant unsuitable for enrollment.

Where this trial is running

Beijing, Beijing Municipality

• Beijing Tiantan Hospital Capital Medical University — Beijing, Beijing Municipality, China (Recruiting)

Study contacts

• Study coordinator: Qian Zhang, MD

Conditions Moyamoya Disease; Conservative management; Long-term follow-up; First-degree relatives